20/20 Biolabs director discloses equity holdings
20/20 Biolabs, Inc. director John Woodson Rollins filed an initial ownership report showing direct holdings of several equity instruments in AIDX.
Rhea-AI Filing Summary
20/20 Biolabs, Inc. director John Woodson Rollins filed an initial ownership report showing direct holdings of several equity instruments in AIDX. He reports 13,029 shares of Series A Preferred Stock and 6,135 shares of Series A-2 Preferred Stock, each convertible into common stock on a one-for-one basis at his option and automatically if the common stock lists on a national exchange. He also holds multiple stock options, including grants for 48,780, 76,628, 37,584, 37,583, 30,000 and 30,000 shares of common stock, with vesting terms described in the notes, and 11,111 shares of common stock directly owned. The filing records existing positions rather than new purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Rollins John Woodson
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Preferred Stock | -- | -- | -- |
| holding | Series A-2 Preferred Stock | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Series A Preferred Stock — 13,029 contracts (Direct);
Series A-2 Preferred Stock — 6,135 contracts (Direct);
Stock Option — 260,575 contracts (Direct);
Common Stock — 11,111 shares (Direct)
Footnotes (8)
- F1. Each share of series A preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A preferred stock has no expiration date.
- F2. Each share of series A-2 preferred stock is convertible into one (1) share of common stock at any time at the option of the Reporting Person. In addition, all outstanding shares of series A-2 preferred stock shall automatically be converted into an equivalent number of shares of common stock on the date on which the Issuer's common stock is listed on a national stock exchange, including without limitation, the New York Stock Exchange or the Nasdaq Stock Market. The series A-2 preferred stock has no expiration date.
- F3. On August 1, 2019, the Reporting Person was granted a stock option for the purchase of 48,780 shares of common stock, which vested in full on the date of grant.
- F4. On January 28, 2021, the Reporting Person was granted a stock option for the purchase of 76,628 shares of common stock, which vested in full on the date of grant.
- F5. On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,584 shares of common stock, which vested in equal monthly installments over 12 months.
- F6. On February 1, 2022, the Reporting Person was granted a stock option for the purchase of 37,583 shares of common stock, which vested in full on the date of grant.
- F7. On January 1, 2023, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.
- F8. On July 1, 2024, the Reporting Person was granted a stock option for the purchase of 30,000 shares of common stock, which vested in equal monthly installments over 12 months.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity holdings does AIDX director John Woodson Rollins report on this Form 3?
John Woodson Rollins reports direct holdings of preferred stock, stock options and common shares. He lists 13,029 Series A Preferred, 6,135 Series A-2 Preferred, several stock option grants, and 11,111 shares of common stock in 20/20 Biolabs, Inc. (AIDX).
How are AIDX Series A and Series A-2 Preferred Stock held by John Woodson Rollins convertible?
Each share of AIDX Series A and Series A-2 Preferred is convertible one-for-one into common stock. Conversion can occur at Rollins’ option at any time, and all outstanding shares convert automatically if AIDX common stock is listed on a national stock exchange.
What stock option grants in AIDX common stock does John Woodson Rollins disclose?
Rollins discloses multiple AIDX stock option grants with specific grant dates and amounts. These include options for 48,780, 76,628, 37,584, 37,583, 30,000 and 30,000 shares, with vesting either fully on grant or in equal monthly installments over 12 months.
What direct common stock ownership in AIDX does John Woodson Rollins report?
Rollins reports direct ownership of 11,111 shares of AIDX common stock. This position is listed separately from his preferred stock and stock option holdings, providing a clear view of his current direct common equity stake in 20/20 Biolabs, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.
